We have located links that may give you full text access.
A reappraisal of the epidemiology of Spitz neoplasms in the molecular era: A retrospective cohort study.
Journal of the American Academy of Dermatology 2023 August 10
BACKGROUND: Previous studies suggests that Spitz neoplasms occur primarily in younger patients, leading pathologists to shy away from diagnosing a benign Spitz neoplasm in the elderly. With the advent of genomic sequencing, there is a need for reappraisal of the epidemiology of Spitz neoplasms in the modern molecular era.
OBJECTIVE: We aim to reassess the epidemiology of Spitz neoplasms incorporating NGS.
METHODS: We looked at 54,814 non-Spitz neoplasms and 1260 Spitz neoplasms including 286 Spitz neoplasms with NGS testing and collected various epidemiologic data.
RESULTS: In our general pool of cases, the proportion of Spitz neoplasm cases occurring is relatively the same in each of the first four decades of life with a precipitous drop in the 5th decade. In assessing a group of genomically verified cases of Spitz neoplasms, the drop was much less significant and up to 20% of all Spitz neoplasm cases occurred in patients over 50 years of age.
LIMITATIONS: Limitations included the number of genetically verified Spitz neoplasm cases available and a possible bias as to which cases undergo genomic testing.
CONCLUSION: Genomic verification may allow more confident diagnosis of Spitz neoplasms in patients over 50 years of age and avoid melanoma overdiagnosis.
OBJECTIVE: We aim to reassess the epidemiology of Spitz neoplasms incorporating NGS.
METHODS: We looked at 54,814 non-Spitz neoplasms and 1260 Spitz neoplasms including 286 Spitz neoplasms with NGS testing and collected various epidemiologic data.
RESULTS: In our general pool of cases, the proportion of Spitz neoplasm cases occurring is relatively the same in each of the first four decades of life with a precipitous drop in the 5th decade. In assessing a group of genomically verified cases of Spitz neoplasms, the drop was much less significant and up to 20% of all Spitz neoplasm cases occurred in patients over 50 years of age.
LIMITATIONS: Limitations included the number of genetically verified Spitz neoplasm cases available and a possible bias as to which cases undergo genomic testing.
CONCLUSION: Genomic verification may allow more confident diagnosis of Spitz neoplasms in patients over 50 years of age and avoid melanoma overdiagnosis.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app